An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
ConditionLennox Gastaut Syndrome
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age4+
SponsorEisai Inc.
About this trial
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Eligibility criteria
Qualifiers
Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.
Disqualifiers
Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.
Trial design
Treatments tested in this trial
- Rufinamide
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov